Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDY-mAbs Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 3 | -$0.16 | -$0.12 | -$0.14 |
| Q2 2024 | 3 | -$0.15 | -$0.11 | -$0.12 |
| Q3 2024 | 3 | -$0.19 | -$0.14 | -$0.16 |
| Q4 2024 | 8 | -$0.20 | -$0.03 | -$0.11 |
| Q1 2025 | 4 | -$0.21 | -$0.04 | -$0.15 |
| Q2 2025 | 2 | -$0.21 | -$0.15 | -$0.17 |
| Q3 2025 | 2 | -$0.20 | -$0.15 | -$0.17 |
| Q4 2025 | 2 | -$0.19 | -$0.14 | -$0.16 |
Y-mAbs Therapeutics, Inc. Earnings Date And Information
Y-mAbs Therapeutics, Inc. last posted its earnings results on Friday, November 8th, 2024. The company reported $-0.16 earnings per share for the quarter, missing analysts' consensus estimates of $-0.14 by $0.02. The company had revenue of 18.46 M for the quarter and had revenue of 84.82 M for the year. Y-mAbs Therapeutics, Inc. has generated $0 earnings per share over the last year ($-0.49 diluted earnings per share) and currently has a price-to-earnings ratio of -15.48. Y-mAbs Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based on prior year's report dates.
Y-mAbs Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/08/2024 | Q3 2024 | -$0.14 | -$0.16 | -0.02 | $23.28 M | $18.46 M |
| 08/12/2024 | Q2 2024 | -$0.21 | $23.02 M | $22.80 M | ||
| 05/07/2024 | Q1 2024 | -$0.12 | -$0.15 | -0.03 | $19.93 M | |
| 02/29/2024 | Q4 2023 | -$0.19 | -$0.02 | 0.17 | $23.36 M | |
| 11/13/2023 | Q3 2023 | -$0.16 | -$0.18 | -0.02 | $20.97 M | $20.45 M |
| 08/10/2023 | Q2 2023 | -$0.24 | -$0.14 | 0.1 | $20.33 M | $20.75 M |
| 05/08/2023 | Q1 2023 | -$0.31 | -$0.12 | 0.19 | $20.25 M | |
| 03/30/2023 | Q4 2022 | -$0.44 | -$0.01 | 0.43 | $31.45 M | |
| 11/07/2022 | Q3 2022 | -$0.75 | -$0.66 | 0.09 | $12.01 M | $12.54 M |
| 08/08/2022 | Q2 2022 | -$0.68 | -$0.97 | -0.29 | $11.23 M | $10.80 M |
| 05/09/2022 | Q1 2022 | -$0.71 | -$0.65 | 0.06 | $10.49 M | |
| 03/01/2022 | Q4 2021 | -$0.85 | $9.60 M | |||
| 11/04/2021 | Q3 2021 | -$0.60 | -$0.66 | -0.06 | $10.87 M | $8.97 M |
| 08/09/2021 | Q2 2021 | -$0.53 | $7.33 M | $10.95 M | ||
| 05/06/2021 | Q1 2021 | $0.61 | $0.80 | 0.19 | $5.38 M | |
| 03/01/2021 | Q4 2020 | -$0.48 | $20.75 M | |||
| 11/05/2020 | Q3 2020 | -$0.80 | -$0.82 | -0.02 | $0 | |
| 08/06/2020 | Q2 2020 | -$0.69 | -$1.01 | -0.32 | $0 | |
| 05/07/2020 | Q1 2020 | -$0.63 | -$0.66 | -0.03 | $0 | |
| 03/12/2020 | Q4 2019 | -$0.67 | -$0.61 | 0.06 | $0 |
Y-mAbs Therapeutics, Inc. Earnings: FAQ's
When is Y-mAbs Therapeutics, Inc.'s earnings date?
Y-mAbs Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based off last year's report dates.
How can I listen to Y-mAbs Therapeutics, Inc.'s earnings conference
call?
The conference call for Y-mAbs Therapeutics, Inc.'s latest earnings report can be listened to online.
How can I read Y-mAbs Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Y-mAbs Therapeutics, Inc.'s latest earnings report can be read online.
How much revenue does Y-mAbs Therapeutics, Inc. generate each year?
Y-mAbs Therapeutics, Inc. (:YMAB) has a recorded annual revenue of $84.82 M.
How much profit does Y-mAbs Therapeutics, Inc. generate each year?
Y-mAbs Therapeutics, Inc. (:YMAB) has a recorded net income of $84.82 M. Y-mAbs Therapeutics, Inc. has generated $-0.49 earnings per share over the last four quarters.
What is Y-mAbs Therapeutics, Inc.'s price-to-earnings ratio?
Y-mAbs Therapeutics, Inc. (:YMAB) has a price-to-earnings ratio of -15.48 and price/earnings-to-growth ratio is -4.34.